PD-(L)1 Inhibitors Market to Remarkable Growth at a CAGR of 5% by 2034 in the 7MM| DelveInsight [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
Among the 10 approved drugs, early entrants OPDIVO and KEYTRUDA continue to command a major share of the market. LAS VEGAS July 2, 2024 /PRNewswire/ -- DelveInsight's PD-(L)1 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging PD-(L)1 inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany France Italy , and Spain ) and the United Kingdom , and Japan ]. Key Takeaways from the PD-(L)1 Inhibitors Market Report According to DelveInsight's analysis, the market size of PD-(L)1 inhibitors in the 7MM was nearly USD 36 billion in 2023, and the largest market size was generated by the United States In the competitive landscape of PD-1 inhibitors, KEYTRUDA dominates the US market, while OPDIVO leads in Japan LIBTAYO is the market leader for non-melanoma skin cancers, such as cutaneous squamous cell carcinoma and ba
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Novo Nordisk reprimanded in U.K. for failing to disclose payments to health care sector [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector [Yahoo! Finance Canada]Yahoo! Finance Canada
- Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector [Yahoo! Finance]Yahoo! Finance
- Oncology Nutrition Market is expected to grow at 7.14 % CAGR from 2023 to 2030 - Exactitude Consultancy [Yahoo! Finance]Yahoo! Finance
- Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 68% of the company [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 5/1/24 - Beat
PFE
Sec Filings
- 7/1/24 - Form 4
- 7/1/24 - Form 4
- 7/1/24 - Form 4
- PFE's page on the SEC website